HSBC Analysts Give Carl Zeiss Meditec (AFX) a €84.00 Price Target

HSBC set a €84.00 ($97.67) target price on Carl Zeiss Meditec (ETR:AFX) in a research note released on Tuesday morning, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.

A number of other equities analysts also recently issued reports on AFX. Berenberg Bank set a €80.00 ($93.02) price objective on shares of Carl Zeiss Meditec and gave the stock a neutral rating in a report on Wednesday, May 22nd. Deutsche Bank set a €80.00 ($93.02) price objective on shares of Carl Zeiss Meditec and gave the stock a neutral rating in a report on Friday, May 17th. Nord/LB set a €92.00 ($106.98) price objective on shares of Carl Zeiss Meditec and gave the stock a neutral rating in a report on Wednesday, May 8th. Independent Research set a €76.50 ($88.95) price objective on shares of Carl Zeiss Meditec and gave the stock a neutral rating in a report on Monday, April 15th. Finally, Hauck & Aufhaeuser set a €78.50 ($91.28) price objective on shares of Carl Zeiss Meditec and gave the stock a neutral rating in a report on Thursday, February 14th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus price target of €78.25 ($90.99).

Shares of AFX stock opened at €85.85 ($99.83) on Tuesday. Carl Zeiss Meditec has a 52 week low of €56.90 ($66.16) and a 52 week high of €90.60 ($105.35). The company has a market capitalization of $7.68 billion and a PE ratio of 59.87. The company has a debt-to-equity ratio of 4.55, a current ratio of 4.11 and a quick ratio of 3.09.

About Carl Zeiss Meditec

Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally. It operates through two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery.

Further Reading: How a Strangle Strategy is different from a Straddle Strategy

Analyst Recommendations for Carl Zeiss Meditec (ETR:AFX)

Receive News & Ratings for Carl Zeiss Meditec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carl Zeiss Meditec and related companies with MarketBeat.com's FREE daily email newsletter.